Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma

Wei Song; Kai Wang; Fu-ping Zhong; You-wen Fan; Lang Peng; Shu-bing Zou

doi:10.18632/oncotarget.13244

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma

Wei Song, Kai Wang, Fu-ping Zhong, You-wen Fan, Lang Peng and Shu-bing Zou _

PDF | HTML | How to cite

Oncotarget. 2016; 7:81830-81838. https://doi.org/10.18632/oncotarget.13244

Metrics: PDF 1673 views | HTML 1980 views | ?

Abstract

Wei Song1,*, Kai Wang1,*, Fu-ping Zhong1, You-wen Fan1, Lang Peng1, Shu-bing Zou1

1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

*These authors have contributed equally to this work

Correspondence to:

Shu-bing Zou, email: [email protected]

Keywords: platelet to lymphocyte ratio (PLR), hepatocellular carcinoma, biomarker, prognosis, meta-analysis

Received: September 07, 2016 Accepted: October 17, 2016 Published: November 09, 2016

ABSTRACT

The platelet-to-lymphocyte ratio (PLR) is reported to be a prognostic factor in multiple malignancies. The aim of this study was to assess its prognostic value in hepatocellular carcinoma (HCC). We performed comprehensive searches of electronic databases for relevant studies. A total of eleven studies comprising 2,507 patients were included. Elevated PLR was significantly associated with poor overall survival (OS) (HR = 1.78; 95% CI = 1.36-2.34; P < 0.001) and disease-free survival (DFS)/recurrence-free survival (RFS) (HR = 1.82; 95% CI = 1.56-2.13; P < 0.001). The findings from most subgroup analyses were consistent with those from the overall analysis. In addition, a high PLR correlated with tumor size > 3 cm, TNM stage, lymph node metastasis, distant metastasis, and vascular invasion. We therefore conclude that elevated pretreatment PLR may be predicative of a poor prognosis in patients with HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13244

Publication Alerts

Research Papers:

Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma

Abstract